Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q4 FY25 results · Jan–Mar 2025
Gufic Biosciences reported revenue from operations of ₹205.02 crore (up 5.1% from Q4 FY24) and net profit of ₹7.72 crore (down 61.5% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 205.02 | 194.99 | +5.1% | 207.79 | −1.3% |
| Other income | 0.39 | 0.88 | −55.2% | 1.86 | −78.8% |
| Total income | 205.41 | 195.87 | +4.9% | 209.66 | −2.0% |
| Profit before tax | 10.52 | 27.12 | −61.2% | 26.26 | −59.9% |
| Net profit for the period | 7.72 | 20.05 | −61.5% | 19.31 | −60.0% |
| EPS, basic (₹) | 0.77 | 2.00 | −61.5% | 1.93 | −60.1% |
| Net margin (%) | 3.8 | 10.3 | 9.3 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 205.02 | 194.99 | +5.1% | 207.79 | −1.3% |
| Other income | 0.38 | 0.88 | −56.5% | 1.86 | −79.4% |
| Total income | 205.40 | 195.87 | +4.9% | 209.66 | −2.0% |
| Profit before tax | 10.78 | 27.12 | −60.3% | 26.28 | −59.0% |
| Net profit for the period | 7.97 | 20.05 | −60.2% | 19.32 | −58.7% |
| EPS, basic (₹) | 0.80 | 2.00 | −60.0% | 1.93 | −58.5% |
| Net margin (%) | 3.9 | 10.3 | 9.3 |
Consolidated
- Filed with BSE
- 30 May 2025, 20:54 IST
- Board meeting
- 30 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 May 2025, 20:54 IST
- Board meeting
- 30 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE